Researchers at the University of Manchester found that flare-ups in chronic obstructive pulmonary disease can be reduced by 20% with a combined triple inhaler. The team’s work was published in the Lancet. The 2,691-patient trial compared an inhaler that delivers 3 different compounds to a commonly-used inhaler. Another sub-set of patients were administered a triple combination […]
Respiratory
Capsugel expands into late-stage inhalation delivery
Capsugel said today that it expanded its late-stage inhalation formulation capabilities to move dry powder inhalation concepts through late-stage clinical trial and into commercial production. The company installed a new Harro Hofliger Modu-C MS encapsulation unit at its Oregon-based facility. The machinery features specialized drum-dosing tech for use in dry powder inhalation development projects with […]
Acorda plans NDA for inhaled Parkinson’s drug after touting long-term safety data
Acorda Therapeutics (NSDQ:ACOR) touted data from 2 ongoing, long-term safety studies of its inhaled Parkinson’s therapy. The trials showed no difference in pulmonary function between the group receiving CVT-301, the inhaled formulation of Parkinson’s drug levodopa, and the control group. The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” […]
Mylan shares down -3% after FDA rejects Advair generic
Shares in Mylan (NSDQ:MYL) dropped -3% to $40.46 apiece today after the FDA rejected its Abbreviated New Drug Application for the generic version of GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus. The Canonsburg, Penn.-based company said it is “in the process of reviewing this response and will provide an update on its application as soon as practicable once it has […]
Pulmatrix jumps 8% on rumors of potential Mylan takeover bid
Shares in Pulmatrix (NSDQ:PULM) jumped more than 8% today on rumors that the company’s collaboration partner Mylan (NSDQ:MYL) may be interested in a takeover bid. In 2015, the 2 companies inked an ex-U.S. development deal for PUR0200, Pulmatrix’s investigational bronchodilator for the treatment of chronic obstructive pulmonary disease. Mylan had an option on the rights […]
Cohero Health oversubscribes Series A for connected respiratory tech
Cohero Health said today that it oversubscribed its $9 million Series A round with investments from Samsung Next and Omron Healthcare The latest contributions will be used to support commercialization of hardware and software for its BreatheSmart connected respiratory disease management platform, the N.Y.-based company said. “BreatheSmart from Cohero Health provides both connected hardware and software as […]
Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide
Glenmark Pharmaceuticals said today that the FDA approved its Investigational New Drug application for a Phase II study of its nebulized tiotropium bromide. The Mahwah, N.J.-based company plans to enroll 155 patients with mild to moderate chronic obstructive pulmonary disease and evaluate its GSP 304 formulation as a daily maintenance treatment for bronchospasm. “Respiratory is a core […]
Demand for EpiPen alternatives jumps as states consider access legislation
Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007. Generic […]
Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution
Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals inked a deal with the University of Pittsburgh related to its phase 1/2 open-label proof-of-concept trial for the company’s AIR001 inhaled sodium nitrite solution in patients with cystic fibrosis. The study will evaluate the nebulized drug as a treatment of Pseudomonas aeruginosa infection in CF […]
Study: Patient error cuts dose in half for inhalers
Researchers from Rice University and Baylor College of Medicine have identified patient errors that cause inhaler users to get about half as much medicine as they should from each dose. The team said that clinicians have known for years that patients don’t use their inhalers as prescribed, but inhaler-dosing studies tend to focus on the rare cases […]